Rehospitalizations and direct medical costs for cSSSI: Linezolid versus vancomycin

American Journal of Pharmacy Benefits

Volumn 5, Issue 6, 2013, Pages 258-267

  Daniel Mullins, C ^a   Keri Yang, H ^a   Onukwugha, Eberechukwu ^a   Eisenberg, Debra F ^b   Myers, Daniela E ^c   Huang, David B ^c   Lodise, Thomas ^d  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b HEALTHCORE INC   (United States)

^c PFIZER INC   (United States)

^d ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LINEZOLID; VANCOMYCIN;

ADULT; ARTICLE; BACTERIAL ENDOCARDITIS; COMPLICATED SKIN AND SKIN STRUCTURE INFECTION; GANGRENE; HOSPITAL COST; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MENINGITIS; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NECROTIZING FASCIITIS; SKIN INFECTION; TREATMENT OUTCOME;

EID: 84891365382     PISSN: 19454481     EISSN: 21642494     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Hersh AL, Chambers HF, Maselli JH, Gonzales R. National trends in ambulatory visits and antibiotic prescribing for skin and soft-tissue infections. Arch Intern Med. 2008;168(14):1585-1591.
2. US Food and Drug Administration. Guidance for industry: acute bacterial skin and skin structure infections: developing drugs for treatment: draft guidance. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071185.pdf. Published August 2010. Accessed November 12,2011.
3. Nichols RL. Optimal treatment of complicated skin and skin structure infections. J Antimicrob Chemother. 1999;44(suppl A):19-23.
4. Wright BM, Eiland EH. Retrospective analysis of clinical and cost outcomes associated with methicillin-resistant staphylococcus aureus complicated skin and skin structure infections treated with daptomycin, vancomycin, or linezolid. http://www.hindawi.com/journals/jpath/2011/347969/. J Pathogens. 2011:1-6. Accessed November 12, 2011.
5. Jenkins TC, Sabel AL, Sarcone EE, Price CS, Mehler PS, Burman WJ. Skin andsoft-tissue infections requiring hospitalization at an academic medical center: opportunities for antimicrobial stewardship. Clin Infect Dis. 2010;51(8):895-903.
6. Moet GJ, Jones RN, Biedenbach DJ, Stilwell MG, Fritsche TR. Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). Diagn Microbiol Infect Dis. 2007;57(1):7-13.
7. Weigelt JA, Lipsky BA, Tabak YP, Derby KG, Kim M, Gupta V. Surgical site infections: causative pathogens and associated outcomes. Am J Infect Control. 2010; 38(2):112-120.
8. Talan DA, Krishnadasan A, Gorwitz RJ, et al; EMERGEncy ID Net Study Group. Comparison of Staphylococcus aureus from skin and soft-tissue infections in US emergency department patients, 2004 and 2008. Clin Infect Dis. 2011;53(2): 144-149.
9. Yates C, May K, Hale T, et al. Wound chronicity, inpatient care, and chronic kidney disease predispose to MRSA infection in diabetic foot ulcers. Diabetes Care. 2009;32(10):1907-1909.
10. Moran GJ, Krishnadasan A, Gorwitz RJ, et al; EMERGEncy ID Net Study Group. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med. 2006;355(7):666-674.
11. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011;52(3):285-292.
12. Liu C, Bayer A, Cosgrove SE, et al; Infectious Diseases Society of America. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children [published correction appears in Clin Infect Dis. 2011;53(3):319]. Clin Infect Dis. 2011;52(3):e18-e55.
13. Stevens DL, Bisno AL, Chambers HF, et al; Infectious Diseases Society of America. Practice guidelines for the diagnosis and management of skin and soft-tissue infections [published corrections appear in Clin Infect Dis. 2005;41(12):1830 and Clin Infect Dis. 2006;42(8):1219]. Clin Infect Dis. 2005;41(10):1373-1406.
14. Itani KM, Dryden MS, Bhattacharyya H, Kunkel MJ, Baruch AM, Weigelt JA. Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus. Am J Surg. 2010;199(6):804-816.
15. Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis. 2002;34(11):1481-1490.
16. Weigelt J, Itani K, Stevens D, Lau W, Dryden M, Knirsch C; Linezolid CSSTI Study Group. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother. 2005;49(6):2260-2266.
17. Drugs. com. Zyvox. http://www.drugs.com/pro/zyvox.html. Revised May 2013. Accessed January 3, 2012.
18. Mullins CD, Hsu VD, Cooke CE, Shelbaya A, Wallace AE, Perencevich EN. Rehospitalization rates among linezolid versus vancomycin users. Am J Pharm Benefits. 2011;3(2):e1-e13.
19. Manning WG, Mullahy J. Estimating log models: to transform or not to transform? J Health Econ. 2001;20(4):461-494.
20. Faries DE, Leon AC, Haro JM, Obenchain RL. Analysis of Observational Health Care Data Using SAS. Cary, NC: SAS Institute Inc; 2010.
21. Sharpe JN, Shively EH, Polk HC Jr. Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. Am J Surg. 2005;189(4):425-428.
22. McKinnon PS, Carter CT, Girase PG, Liu LZ, Carmeli Y. The economic effect of oral linezolid versus intravenous vancomycin in the outpatient setting: the payer perspective. Manag Care Interface. 2007;20(1):23-34.
23. Itani KM, Weigelt J, Li JZ, Duttagupta S. Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA). Int J Antimicrob Agents. 2005;26(6):442-448.
24. Lipsky BA, Itani KM, Weigelt JA, et al. The role of diabetes mellitus in the treatment of skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus: results from three randomized controlled trials. Int J Infect Dis. 2011;15(2):e140-e146.
25. McCollum M, Sorensen SV, Liu LZ. A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft-tissue infections caused by suspected or confirmed methicillin-resistant Staphylococcus aureus in elderly US patients. Clin Ther. 2007;29(3):469-477.
26. McKinnon PS, Sorensen SV, Liu LZ, Itani KM. Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections. Ann Pharmacother. 2006;40(6): 1017-1023.
27. Patanwala AE, Erstad BL, Nix DE. Cost-effectiveness of linezolid and vancomycin in the treatment of surgical site infections. Curr Med Res Opin. 2007;23(1): 185-193.
28. Li JZ, Willke RJ, Rittenhouse BE, Rybak MJ. Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin-resistant staphylococci: results from a randomized clinical trial. Surg Infect (Larchmt). 2003;4(1):57-70.
29. Bounthavong M, Hsu DI, Okamoto MP. Cost-effectiveness analysis of linezolid vs. vancomycin in treating methicillin-resistant Staphylococcus aureus complicated skin and soft tissue infections using a decision analytic model. Int J Clin Pract. 2009;63(3):376-386.
30. National Priorities Partnership, convened by the National Quality Forum. Preventing Hospital Readmissions: A $25 Billion Opportunity. http://www.qualityforum.org/NPP/docs/Preventing_Hospital_Readmissions_CAB.aspx. Published November 2010. Accessed February 1, 2013.
31. Graves N, McGowan JE Jr. Nosocomial infection, the Deficit Reduction Act, and incentives for hospitals. JAMA. 2008;300(13):1577-1579.